HDAC inhibitors have been developed for cancer therapy in a variety of both solid and hematological malignancies, and transcriptional profiling of MM suggest HDAC inhibitors may be an attractive therapeutic target for the treatment of MM [14–17]. The gene discussed is HDAC9; the disease is hematologic disorder.